×
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Chronic Idiopathic Constipation Market Share

ID: MRFR/Pharma/4475-HCR
100 Pages
Rahul Gotadki
October 2025

Chronic Idiopathic Constipation Market Research Report Information By Diagnosis (Blood Tests, Sigmoidoscopy, Colonoscopy, Balloon Expulsion Test, Anorectal Manometry), Treatment (Drugs), End-User (Hospitals & Clinics, Diagnostic Centers) -Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Chronic Idiopathic Constipation Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF

Market Share

Chronic Idiopathic Constipation Market Share Analysis

Among the integral domains in gastrointestinal healthcare is Chronic Idiopathic Constipation (CIC) market, which is grappling with stiffer competition that has necessitated different market share positioning strategies by firms. Furthermore, businesses’ success and sustainability within this dynamic environment depend on effective strategies for success in CIC market. Investing in research and development to introduce innovative therapies and treatment options is an important way of moving forward with this strategy. By offering advanced medications and treatments, companies seek to differentiate themselves for better management of chronic idiopathic constipation conditions characterized by persistent, difficult-to-treat constipation without a known cause. This strategic approach meets the rising demand for accurate and efficient solutions facilitating such unique challenges as perennial constipation.

The pricing strategies play a role in determining the market share within Chronic idiopathic constipation market. Companies often use various pricing models like premium pricing for medication with added benefits as well as affordable options to increase patients’ accessibility. They price their products based on their perceived value that would cater for different markets such as hospital looking forward to state-of-the-art solutions or countries having different economic situations. For instance, through flexible pricing model they are able to be accessible throughout any given market thus broadening their reach.

Strategic collaborations and partnerships are key drivers in market share positioning for the CIC market. Collaborative projects involving these entities enhance knowledge sharing while at the same time putting diagnosis and treatment options into limelight. On one hand, these organizations exploit their partners’ strengths so as to gain competitive advantage in terms of research capabilities, marketing insights or distribution networks thus shoring up their overall presence.

Another important strategy used by companies is segmenting the customer base so that they can effectively target diverse groups within the Chronic Idiopathic Constipation (CIC) market. Medications tailored specifically towards meeting specific challenges faced by gastroenterologists, primary care physicians and patients suffering from CIC tend to have greater acceptability and usage by target markets. Different marketing mix strategies coupled with product portfolios are then developed to suit the unique requirements of these segments, thus enhancing their market position.

The positioning of companies’ market shares is significantly influenced by patient-centered approaches such as comprehensive support programs for patients and educational activities. Companies that offer assistance services, training resources and convenient communication measures targeting at satisfying patients or medical service providers are more likely to gain trust and loyalty from their stakeholders. This way, a company can have an increasing number of satisfied customers who would not only advocate for it but also recommend it to other potential customers thereby affecting its market share positively.

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

Leave a Comment

FAQs

What is the current valuation of the Chronic Idiopathic Constipation Market?

The market valuation reached 4.897 USD Billion in 2024.

What is the projected market size for Chronic Idiopathic Constipation by 2035?

The market is expected to grow to 10.48 USD Billion by 2035.

What is the expected CAGR for the Chronic Idiopathic Constipation Market during the forecast period?

The market is projected to experience a CAGR of 7.16% from 2025 to 2035.

Which companies are the key players in the Chronic Idiopathic Constipation Market?

Key players include AbbVie, Boehringer Ingelheim, Takeda Pharmaceutical Company, and Ironwood Pharmaceuticals.

What are the primary segments of the Chronic Idiopathic Constipation Market?

The market segments include Diagnosis, Treatment, and End-User Industries.

Market Summary

As per MRFR analysis, the Chronic Idiopathic Constipation Market was estimated at 4.897 USD Billion in 2024. The Chronic Idiopathic Constipation industry is projected to grow from 5.248 USD Billion in 2025 to 10.48 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 7.16 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Chronic Idiopathic Constipation Market is experiencing a transformative shift towards personalized and technologically integrated treatment solutions.

  • The demand for personalized treatments is rising, reflecting a broader trend towards individualized healthcare. Technological integration in treatment options is becoming increasingly prevalent, enhancing patient engagement and outcomes. Preventive care and education initiatives are gaining traction, particularly in North America, to address gastrointestinal health. The increasing prevalence of chronic idiopathic constipation and advancements in pharmaceutical research are driving market growth, especially in the laxatives and antidiarrheal segment.

Market Size & Forecast

2024 Market Size 4.897 (USD Billion)
2035 Market Size 10.48 (USD Billion)
CAGR (2025 - 2035) 7.16%
Largest Regional Market Share in 2024 North America

Major Players

<p><a href="https://news.abbvie.com/2022-12-16-AbbVie-Submits-Supplemental-New-Drug-Application-to-U-S-FDA-to-Support-New-Indication-of-LINZESS-R-linaclotide-for-Functional-Constipation-in-Children-and-Adolescents-6-to-17-Years-of-Age">AbbVie </a>(US), Boehringer Ingelheim (DE), Takeda Pharmaceutical Company (JP),<a href="https://investor.ironwoodpharma.com/press-releases/press-release-details/2023/Ironwood-Pharmaceuticals-Announces-FDA-Approval-of-New-Indication-for-LINZESS-linaclotide-for-the-Treatment-of-Functional-Constipation-in-Pediatric-Patients-Ages-6-17-Years-Old/default.aspx"> Ironwood Pharmaceuticals (</a>US), Sucampo Pharmaceuticals (US), AstraZeneca (GB), Salix Pharmaceuticals (US), GSK (GB), MediGene AG (DE)</p>

Market Trends

The Chronic Idiopathic Constipation Market is currently experiencing notable transformations driven by various factors. Increased awareness regarding gastrointestinal health has led to a rise in demand for effective treatment options. Patients are becoming more proactive in seeking solutions, which has prompted pharmaceutical companies to innovate and expand their product offerings. Additionally, the aging population is contributing to a higher prevalence of chronic conditions, including constipation, thereby amplifying the need for targeted therapies. As a result, healthcare providers are focusing on personalized treatment plans that cater to individual patient needs, enhancing overall patient satisfaction. Moreover, advancements in research and development are paving the way for novel therapies that address the underlying causes of chronic idiopathic constipation. The integration of technology in treatment approaches, such as digital health solutions and telemedicine, is also gaining traction. This shift not only improves accessibility but also allows for better monitoring of patient progress. As the market evolves, stakeholders must remain vigilant to emerging trends and adapt their strategies accordingly to maintain a competitive edge in this dynamic landscape.

Rising Demand for Personalized Treatments

There is a growing trend towards personalized medicine in the Chronic Idiopathic Constipation Market. Patients are increasingly seeking tailored therapies that address their specific symptoms and underlying causes. This shift is prompting healthcare providers to develop individualized treatment plans, enhancing patient outcomes and satisfaction.

Technological Integration in Treatment

The incorporation of technology into treatment modalities is becoming more prevalent. Digital health solutions, including mobile applications and telehealth services, are facilitating better patient engagement and monitoring. This trend is likely to improve adherence to treatment regimens and provide healthcare professionals with valuable insights into patient progress.

Focus on Preventive Care and Education

There is an emerging emphasis on preventive care and patient education within the Chronic Idiopathic Constipation Market. Healthcare providers are increasingly prioritizing awareness campaigns and educational resources to empower patients. This proactive approach aims to reduce the incidence of chronic constipation and promote healthier lifestyle choices.

Chronic Idiopathic Constipation Market Market Drivers

Advancements in Pharmaceutical Research

Innovations in pharmaceutical research are significantly influencing the Chronic Idiopathic Constipation Market. Recent developments in drug formulations and delivery systems have led to the introduction of novel therapies that target the underlying mechanisms of constipation. For instance, medications that enhance gastrointestinal motility or modify gut microbiota are gaining traction. The market is projected to witness a compound annual growth rate of around 5% over the next few years, driven by these advancements. Furthermore, ongoing clinical trials and research initiatives are likely to yield new treatment options, thereby expanding the therapeutic landscape and enhancing patient outcomes in the Chronic Idiopathic Constipation Market.

Integration of Digital Health Solutions

The integration of digital health solutions is emerging as a transformative driver in the Chronic Idiopathic Constipation Market. Telehealth services and mobile health applications are facilitating remote consultations and personalized treatment plans for patients suffering from chronic idiopathic constipation. These technologies not only enhance patient engagement but also improve access to healthcare professionals, particularly in underserved areas. As digital health continues to evolve, it is expected to play a crucial role in monitoring patient progress and adherence to treatment regimens. This trend may lead to improved outcomes and increased market penetration for digital solutions within the Chronic Idiopathic Constipation Market.

Rising Demand for Over-the-Counter Solutions

The demand for over-the-counter (OTC) solutions for chronic idiopathic constipation is on the rise, significantly impacting the Chronic Idiopathic Constipation Market. Consumers are increasingly seeking accessible and convenient treatment options that do not require a prescription. This trend is particularly evident among younger populations who prefer self-management of their health conditions. The OTC segment is expected to grow as manufacturers introduce a variety of laxatives and dietary supplements aimed at alleviating constipation symptoms. This shift towards self-care and the availability of effective OTC products are likely to drive market expansion within the Chronic Idiopathic Constipation Market.

Increasing Prevalence of Chronic Idiopathic Constipation

The rising incidence of chronic idiopathic constipation is a pivotal driver for the Chronic Idiopathic Constipation Market. Studies indicate that approximately 14% of the population experiences this condition, with a notable increase in prevalence among older adults. This demographic shift, coupled with lifestyle changes such as poor dietary habits and sedentary behavior, contributes to a growing patient population. As awareness of gastrointestinal health expands, more individuals seek medical advice, leading to increased demand for effective treatments. The Chronic Idiopathic Constipation Market is thus poised for growth, as healthcare providers and pharmaceutical companies respond to this rising need with innovative therapies and solutions.

Growing Awareness and Education on Gastrointestinal Health

The increasing focus on gastrointestinal health education is a crucial driver for the Chronic Idiopathic Constipation Market. Public health campaigns and educational initiatives are raising awareness about the symptoms and treatment options available for chronic idiopathic constipation. This heightened awareness encourages individuals to seek medical consultation, thereby increasing diagnosis rates. As a result, healthcare providers are more likely to recommend appropriate therapies, contributing to market growth. Additionally, the integration of educational resources into healthcare settings fosters a better understanding of preventive measures, which may further influence the Chronic Idiopathic Constipation Market positively.

Market Segment Insights

By Diagnosis: Sigmoidoscopy (Largest) vs. Colonoscopy (Fastest-Growing)

<p>In the Chronic Idiopathic Constipation Market, the diagnosis segment is primarily driven by a variety of diagnostic tools. Sigmoidoscopy holds the largest market share, owing to its effectiveness and relatively low cost compared to other methods. It is often the first choice for physicians when examining the lower part of the colon, making it a common practice for diagnosing chronic idiopathic constipation. Meanwhile, the <a href="https://www.marketresearchfuture.com/reports/colonoscope-market-27611">colonoscopy</a> segment is increasingly gaining traction as awareness of its benefits for comprehensive analysis of the entire colon grows. Other diagnostic methods, like blood tests and anorectal manometry, hold smaller shares but play crucial roles in the overall diagnosis process.</p>

<p>Sigmoidoscopy (Dominant) vs. Colonoscopy (Emerging)</p>

<p>Sigmoidoscopy remains the dominant diagnostic tool in the Chronic Idiopathic Constipation Market, known for its minimally invasive nature and ability to yield immediate results. Physicians frequently prefer this method due to its capability to visually assess the sigmoid colon and rectum, identifying any abnormalities that may cause constipation. It is particularly advantageous for patients due to its shorter recovery time. In contrast, colonoscopy, though less common initially, is emerging as an essential diagnostic procedure in determining the broader causes of constipation. Its growing acceptance is fueled by advancements in technology and increased physician familiarity, leading to improved patient outcomes and further research into its benefits.</p>

By Treatment: Laxatives and Antidiarrheal (Largest) vs. Lubiprostone (Amitiza) (Fastest-Growing)

<p>In the Chronic Idiopathic Constipation Market, the treatment segment is diverse, comprising various options such as laxatives and antidiarrheal agents, which hold the largest market share. This category has established itself as the go-to choice for many patients, solidifying its position as a staple in treatment protocols. Other notable contributors include lubricants, antiemetics, and surgery, each sharing a smaller portion of the market. The diverse array of treatments allows for personalized approaches, catering to the varying needs of patients suffering from chronic idiopathic constipation. The growth trends within this segment reveal a shift towards newer treatment modalities, particularly the integration of drugs like Lubiprostone (Amitiza), which has seen rapid adoption due to its effectiveness and convenience. Additionally, increasing awareness of chronic idiopathic constipation and advancements in drug formulations are driving growth. Substantial investments in research are aimed at improving existing therapies and developing novel solutions, positioning the treatment segment for continued expansion in the years to come.</p>

<p>Laxatives (Dominant) vs. Lubiprostone (Amitiza) (Emerging)</p>

<p>Laxatives, as the dominant treatment for chronic idiopathic constipation, offer a range of options that cater to diverse patient needs, including bulk-forming agents, osmotic laxatives, and stimulant laxatives. These well-established formulations are often the first line of defense due to their availability and efficacy. Meanwhile, Lubiprostone (Amitiza) is emerging rapidly within the market, offering targeted relief for patients who do not benefit from traditional laxatives. Its unique mechanism of action targets intestinal chloride channels, enhancing fluid secretion and promoting bowel movements, making it particularly appealing for chronic idiopathic constipation sufferers. The growing preference for Lubiprostone is indicative of a broader trend towards personalized medicine, with more healthcare providers considering patient-specific factors in treatment plans.</p>

By End-User Industries: Hospitals (Largest) vs. Gastroenterology Clinics (Fastest-Growing)

<p>In the Chronic Idiopathic Constipation Market (CIC) market, the distribution of end-user industries shows hospitals as the largest segment. Their significant share emphasizes the crucial role these institutions play in the diagnosis and management of CIC cases. Gastroenterology clinics are emerging as vital players, increasingly sought after by patients for specialized care and treatment options tailored to their needs. As trends shift toward more specialized and patient-focused care, gastroenterology clinics are rapidly growing in popularity and market share. This can be attributed to an increase in awareness about gastrointestinal health and the effectiveness of targeted treatment plans. Furthermore, technological advancements such as telemedicine are making these clinics more accessible, contributing to their position as the fastest-growing segment within this market.</p>

<p>Hospitals (Dominant) vs. Diagnostic Centers (Emerging)</p>

<p>Hospitals continue to dominate the Chronic Idiopathic Constipation Market, as they provide comprehensive healthcare services including diagnosis, treatment, and long-term management of CIC. These institutions are equipped with advanced medical technologies and highly trained professionals, ensuring patients receive quality care and tailored treatment plans. Conversely, diagnostic centers have emerged as an essential component of the CIC landscape; they offer specialized testing services and often collaborate with physicians for thorough evaluations. The increase in demand for prompt diagnostic services, combined with the rise in awareness regarding gastrointestinal disorders, has positioned diagnostic centers as a rapidly growing segment. Their ability to provide focused and swift assessments of intestinal health allows them to cater to the nuanced needs of patients, ensuring timely diagnosis and effective treatment planning.</p>

Get more detailed insights about Chronic Idiopathic Constipation Market Research Report – Forecast to 2035

Regional Insights

Key Companies in the Chronic Idiopathic Constipation Market market include

Industry Developments

  • Q1 2024: Ironwood Pharmaceuticals Announces FDA Approval of LINZESS® (linaclotide) for Pediatric Patients Aged 6-17 Years with Functional Constipation Ironwood Pharmaceuticals received FDA approval for an expanded indication of LINZESS® (linaclotide) to treat pediatric patients aged 6-17 years with functional constipation, marking a significant regulatory milestone in the chronic idiopathic constipation sector.
  • Q2 2024: Takeda and Ferring Pharmaceuticals Announce Strategic Partnership to Co-Develop Novel Constipation Therapies Takeda and Ferring Pharmaceuticals entered a strategic partnership to co-develop new therapies targeting chronic idiopathic constipation, aiming to accelerate innovation and expand treatment options in the market.
  • Q2 2024: Bausch Health Launches New Osmotic Laxative for Chronic Idiopathic Constipation Market in U.S. Market Bausch Health announced the commercial launch of a new osmotic laxative specifically indicated for chronic idiopathic constipation, expanding its gastrointestinal product portfolio in the United States.
  • Q2 2024: Renexxion Ireland Receives FDA Fast Track Designation for Naronapride in Chronic Idiopathic Constipation Market Renexxion Ireland was granted FDA Fast Track designation for its investigational drug Naronapride, intended for the treatment of chronic idiopathic constipation, facilitating expedited regulatory review.
  • Q3 2024: Ardelyx Announces Positive Phase 3 Results for Tenapanor in Chronic Idiopathic Constipation Market Ardelyx reported positive topline results from its Phase 3 clinical trial evaluating Tenapanor for chronic idiopathic constipation, supporting future regulatory submissions and potential market entry.
  • Q3 2024: Vanda Pharmaceuticals Appoints New Chief Medical Officer to Lead Gastrointestinal Drug Development Vanda Pharmaceuticals appointed a new Chief Medical Officer to oversee its gastrointestinal drug development programs, including candidates for chronic idiopathic constipation.
  • Q4 2024: Cosmo Pharmaceuticals Opens New Manufacturing Facility for Constipation Treatments in Italy Cosmo Pharmaceuticals inaugurated a new manufacturing facility in Italy dedicated to producing treatments for chronic idiopathic constipation, increasing its production capacity and supply chain resilience.
  • Q4 2024: RedHill Biopharma Secures $30 Million Series C Funding to Advance Chronic Idiopathic Constipation Market Pipeline RedHill Biopharma closed a $30 million Series C funding round to support the development and commercialization of its chronic idiopathic constipation drug candidates.
  • Q1 2025: Shionogi Receives EMA Approval for New CIC Drug in Europe Shionogi obtained European Medicines Agency (EMA) approval for its new chronic idiopathic constipation drug, enabling commercial launch across European markets.
  • Q1 2025: Salix Pharmaceuticals Announces U.S. Launch of New Extended-Release Constipation Therapy Salix Pharmaceuticals launched a new extended-release therapy for chronic idiopathic constipation in the United States, expanding its gastrointestinal product offerings.
  • Q2 2025: Progenity Inc. Signs Licensing Agreement with Major Pharma for CIC Diagnostic Platform Progenity Inc. entered a licensing agreement with a major pharmaceutical company to commercialize its diagnostic platform for chronic idiopathic constipation, aiming to improve patient management and outcomes.
  • Q2 2025: Theravance Biopharma Announces Positive Results from Phase 2 Study of New CIC Treatment Theravance Biopharma announced positive results from a Phase 2 clinical study of its investigational treatment for chronic idiopathic constipation, supporting further development and potential regulatory filings.

While not a direct diagnostic tool for CIC itself, a significant development in the broader diagnostic approach for chronic bowel symptoms (including constipation) is the strong recommendation by major gastroenterology bodies (like the American College of Gastroenterology - ACG and British Society of Gastroenterology - BSG) to use non-invasive markers like C-reactive protein (CRP) and fecal calprotectin. These blood and stool tests help to effectively rule out inflammatory bowel disease (IBD) in patients with suspected Irritable Bowel Syndrome with Constipation (IBS-C) or unexplained chronic constipation, especially when alarm features are absent.

This reduces the reliance on more invasive diagnostic procedures like colonoscopy unless specific alarm signs are present.

Future Outlook

Chronic Idiopathic Constipation Market Future Outlook

<p>The Chronic Idiopathic Constipation Market is projected to grow at a 7.16% CAGR from 2024 to 2035, driven by increasing prevalence, innovative therapies, and rising awareness.</p>

New opportunities lie in:

  • <p>Development of personalized treatment plans leveraging genetic profiling.</p><p>Expansion of telehealth services for remote patient monitoring.</p><p>Investment in biodegradable drug delivery systems for enhanced patient compliance.</p>

<p>By 2035, the market is expected to achieve substantial growth, reflecting evolving patient needs and innovative solutions.</p>

Market Segmentation

Chronic Idiopathic Constipation Market Diagnosis Outlook

  • blood tests
  • sigmoidoscopy
  • colonoscopy
  • balloon expulsion test
  • anorectal manometry
  • colonic transit study
  • defecography
  • others

Chronic Idiopathic Constipation Market Treatment Outlook

  • drugs
  • surgery
  • acid neutralizers
  • laxatives and antidiarrheal
  • antiemetics
  • antiulcer
  • lubiprostone (amitiza)
  • linaclotide (linzess)
  • misoprostol (Cytotec)
  • colchicine/probenecid (Col-Probenecid)
  • others
  • Onabotulinumtoxin A (Botox)

Chronic Idiopathic Constipation Market End-User Industries Outlook

  • hospitals
  • gastroenterology clinics
  • diagnostic centers
  • others

Report Scope

MARKET SIZE 20244.897(USD Billion)
MARKET SIZE 20255.248(USD Billion)
MARKET SIZE 203510.48(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)7.16% (2024 - 2035)
REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR2024
Market Forecast Period2025 - 2035
Historical Data2019 - 2024
Market Forecast UnitsUSD Billion
Key Companies ProfiledMarket analysis in progress
Segments CoveredMarket segmentation analysis in progress
Key Market OpportunitiesEmerging therapies targeting gut microbiome modulation present opportunities in the Chronic Idiopathic Constipation Market.
Key Market DynamicsRising demand for innovative therapies drives competition and regulatory scrutiny in the Chronic Idiopathic Constipation Market.
Countries CoveredNorth America, Europe, APAC, South America, MEA

FAQs

What is the current valuation of the Chronic Idiopathic Constipation Market?

The market valuation reached 4.897 USD Billion in 2024.

What is the projected market size for Chronic Idiopathic Constipation by 2035?

The market is expected to grow to 10.48 USD Billion by 2035.

What is the expected CAGR for the Chronic Idiopathic Constipation Market during the forecast period?

The market is projected to experience a CAGR of 7.16% from 2025 to 2035.

Which companies are the key players in the Chronic Idiopathic Constipation Market?

Key players include AbbVie, Boehringer Ingelheim, Takeda Pharmaceutical Company, and Ironwood Pharmaceuticals.

What are the primary segments of the Chronic Idiopathic Constipation Market?

The market segments include Diagnosis, Treatment, and End-User Industries.

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. EXECUTIVE SUMMARY
      1. Market Overview
      2. Key Findings
      3. Market Segmentation
      4. Competitive Landscape
      5. Challenges and Opportunities
      6. Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. MARKET INTRODUCTION
      1. Definition
      2. Scope of the study
    2. RESEARCH METHODOLOGY
      1. Overview
      2. Data Mining
      3. Secondary Research
      4. Primary Research
      5. Forecasting Model
      6. Market Size Estimation
      7. Data Triangulation
      8. Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. MARKET DYNAMICS
      1. Overview
      2. Drivers
      3. Restraints
      4. Opportunities
    2. MARKET FACTOR ANALYSIS
      1. Value chain Analysis
      2. Porter's Five Forces Analysis
      3. COVID-19 Impact Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. Healthcare, BY Diagnosis (USD Billion)
      1. blood tests
      2. sigmoidoscopy
      3. colonoscopy
      4. balloon expulsion test
      5. anorectal manometry
      6. colonic transit study
      7. defecography
      8. others
    2. Healthcare, BY Treatment (USD Billion)
      1. drugs
      2. surgery
      3. acid neutralizers
      4. laxatives and antidiarrheal
      5. antiemetics
      6. antiulcer
      7. lubiprostone (amitiza)
      8. linaclotide (linzess)
      9. misoprostol (Cytotec)
      10. colchicine/probenecid (Col-Probenecid)
      11. others
      12. Onabotulinumtoxin A (Botox)
    3. Healthcare, BY End-User Industries (USD Billion)
      1. hospitals
      2. gastroenterology clinics
      3. diagnostic centers
      4. others
    4. Healthcare, BY Region (USD Billion)
      1. North America
      2. Europe
      3. APAC
      4. South America
      5. MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. Competitive Landscape
      1. Overview
      2. Competitive Analysis
      3. Market share Analysis
      4. Major Growth Strategy in the Healthcare
      5. Competitive Benchmarking
      6. Leading Players in Terms of Number of Developments in the Healthcare
      7. Key developments and growth strategies
      8. Major Players Financial Matrix
    2. Company Profiles
      1. AbbVie (US)
      2. Boehringer Ingelheim (DE)
      3. Takeda Pharmaceutical Company (JP)
      4. Ironwood Pharmaceuticals (US)
      5. Sucampo Pharmaceuticals (US)
      6. AstraZeneca (GB)
      7. Salix Pharmaceuticals (US)
      8. GSK (GB)
      9. MediGene AG (DE)
    3. Appendix
      1. References
      2. Related Reports
  6. LIST OF FIGURES
    1. MARKET SYNOPSIS
    2. NORTH AMERICA MARKET ANALYSIS
    3. US MARKET ANALYSIS BY DIAGNOSIS
    4. US MARKET ANALYSIS BY TREATMENT
    5. US MARKET ANALYSIS BY END-USER INDUSTRIES
    6. CANADA MARKET ANALYSIS BY DIAGNOSIS
    7. CANADA MARKET ANALYSIS BY TREATMENT
    8. CANADA MARKET ANALYSIS BY END-USER INDUSTRIES
    9. EUROPE MARKET ANALYSIS
    10. GERMANY MARKET ANALYSIS BY DIAGNOSIS
    11. GERMANY MARKET ANALYSIS BY TREATMENT
    12. GERMANY MARKET ANALYSIS BY END-USER INDUSTRIES
    13. UK MARKET ANALYSIS BY DIAGNOSIS
    14. UK MARKET ANALYSIS BY TREATMENT
    15. UK MARKET ANALYSIS BY END-USER INDUSTRIES
    16. FRANCE MARKET ANALYSIS BY DIAGNOSIS
    17. FRANCE MARKET ANALYSIS BY TREATMENT
    18. FRANCE MARKET ANALYSIS BY END-USER INDUSTRIES
    19. RUSSIA MARKET ANALYSIS BY DIAGNOSIS
    20. RUSSIA MARKET ANALYSIS BY TREATMENT
    21. RUSSIA MARKET ANALYSIS BY END-USER INDUSTRIES
    22. ITALY MARKET ANALYSIS BY DIAGNOSIS
    23. ITALY MARKET ANALYSIS BY TREATMENT
    24. ITALY MARKET ANALYSIS BY END-USER INDUSTRIES
    25. SPAIN MARKET ANALYSIS BY DIAGNOSIS
    26. SPAIN MARKET ANALYSIS BY TREATMENT
    27. SPAIN MARKET ANALYSIS BY END-USER INDUSTRIES
    28. REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS
    29. REST OF EUROPE MARKET ANALYSIS BY TREATMENT
    30. REST OF EUROPE MARKET ANALYSIS BY END-USER INDUSTRIES
    31. APAC MARKET ANALYSIS
    32. CHINA MARKET ANALYSIS BY DIAGNOSIS
    33. CHINA MARKET ANALYSIS BY TREATMENT
    34. CHINA MARKET ANALYSIS BY END-USER INDUSTRIES
    35. INDIA MARKET ANALYSIS BY DIAGNOSIS
    36. INDIA MARKET ANALYSIS BY TREATMENT
    37. INDIA MARKET ANALYSIS BY END-USER INDUSTRIES
    38. JAPAN MARKET ANALYSIS BY DIAGNOSIS
    39. JAPAN MARKET ANALYSIS BY TREATMENT
    40. JAPAN MARKET ANALYSIS BY END-USER INDUSTRIES
    41. SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS
    42. SOUTH KOREA MARKET ANALYSIS BY TREATMENT
    43. SOUTH KOREA MARKET ANALYSIS BY END-USER INDUSTRIES
    44. MALAYSIA MARKET ANALYSIS BY DIAGNOSIS
    45. MALAYSIA MARKET ANALYSIS BY TREATMENT
    46. MALAYSIA MARKET ANALYSIS BY END-USER INDUSTRIES
    47. THAILAND MARKET ANALYSIS BY DIAGNOSIS
    48. THAILAND MARKET ANALYSIS BY TREATMENT
    49. THAILAND MARKET ANALYSIS BY END-USER INDUSTRIES
    50. INDONESIA MARKET ANALYSIS BY DIAGNOSIS
    51. INDONESIA MARKET ANALYSIS BY TREATMENT
    52. INDONESIA MARKET ANALYSIS BY END-USER INDUSTRIES
    53. REST OF APAC MARKET ANALYSIS BY DIAGNOSIS
    54. REST OF APAC MARKET ANALYSIS BY TREATMENT
    55. REST OF APAC MARKET ANALYSIS BY END-USER INDUSTRIES
    56. SOUTH AMERICA MARKET ANALYSIS
    57. BRAZIL MARKET ANALYSIS BY DIAGNOSIS
    58. BRAZIL MARKET ANALYSIS BY TREATMENT
    59. BRAZIL MARKET ANALYSIS BY END-USER INDUSTRIES
    60. MEXICO MARKET ANALYSIS BY DIAGNOSIS
    61. MEXICO MARKET ANALYSIS BY TREATMENT
    62. MEXICO MARKET ANALYSIS BY END-USER INDUSTRIES
    63. ARGENTINA MARKET ANALYSIS BY DIAGNOSIS
    64. ARGENTINA MARKET ANALYSIS BY TREATMENT
    65. ARGENTINA MARKET ANALYSIS BY END-USER INDUSTRIES
    66. REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS
    67. REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT
    68. REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USER INDUSTRIES
    69. MEA MARKET ANALYSIS
    70. GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS
    71. GCC COUNTRIES MARKET ANALYSIS BY TREATMENT
    72. GCC COUNTRIES MARKET ANALYSIS BY END-USER INDUSTRIES
    73. SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS
    74. SOUTH AFRICA MARKET ANALYSIS BY TREATMENT
    75. SOUTH AFRICA MARKET ANALYSIS BY END-USER INDUSTRIES
    76. REST OF MEA MARKET ANALYSIS BY DIAGNOSIS
    77. REST OF MEA MARKET ANALYSIS BY TREATMENT
    78. REST OF MEA MARKET ANALYSIS BY END-USER INDUSTRIES
    79. KEY BUYING CRITERIA OF HEALTHCARE
    80. RESEARCH PROCESS OF MRFR
    81. DRO ANALYSIS OF HEALTHCARE
    82. DRIVERS IMPACT ANALYSIS: HEALTHCARE
    83. RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    84. SUPPLY / VALUE CHAIN: HEALTHCARE
    85. HEALTHCARE, BY DIAGNOSIS, 2024 (% SHARE)
    86. HEALTHCARE, BY DIAGNOSIS, 2024 TO 2035 (USD Billion)
    87. HEALTHCARE, BY TREATMENT, 2024 (% SHARE)
    88. HEALTHCARE, BY TREATMENT, 2024 TO 2035 (USD Billion)
    89. HEALTHCARE, BY END-USER INDUSTRIES, 2024 (% SHARE)
    90. HEALTHCARE, BY END-USER INDUSTRIES, 2024 TO 2035 (USD Billion)
    91. BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. LIST OF ASSUMPTIONS
    2. North America MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    3. US MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    4. Canada MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    5. Europe MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    6. Germany MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    7. UK MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    8. France MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    9. Russia MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    10. Italy MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    11. Spain MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    12. Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    13. APAC MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    14. China MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    15. India MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    16. Japan MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    17. South Korea MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    18. Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    19. Thailand MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    20. Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    21. Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    22. South America MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    23. Brazil MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    24. Mexico MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    25. Argentina MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    26. Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    27. MEA MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    28. GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    29. South Africa MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    30. Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. BY DIAGNOSIS, 2025-2035 (USD Billion)
      2. BY TREATMENT, 2025-2035 (USD Billion)
      3. BY END-USER INDUSTRIES, 2025-2035 (USD Billion)
    31. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    32. ACQUISITION/PARTNERSHIP

Chronic Idiopathic Constipation Market Segmentation

Market Segmentation Overview

  • Detailed segmentation data will be available in the full report
  • Comprehensive analysis by multiple parameters
  • Regional and country-level breakdowns
  • Market size forecasts by segment
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Victoria Milne

Founder
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓